Skip to main content

Table 2 Objective Response rate

From: A phase ΙI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study)

HLA-status

HLA-A*2402-matched

(n = 50)

HLA-A*2402-unmatched

(n = 46)

Response

CR

PR

SD

PD

CR

PR

SD

PD

Number

1

30

16

3

0

28

17

1

Response rate

 

31/50

(62.0%)

  

28/46

(60.9%)